2013-01-16 06:59:17 -
BB BIOTECH AG /
BB Biotech AG earns after-tax profits of CHF 368 million in fiscal 2012
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
In accordance with regulations on ad hoc publicity, BB Biotech (ISIN
CH0038389992) is releasing the following information about its profits in fiscal
Based on preliminary unaudited consolidated results, BB Biotech closed the past
year with a profit of CHF 368 million (loss of CHF 146 million in the previous
year). After three very strong quarters with profits in the triple-digit
millions, general profit-taking in the market towards the end
of the year led to
a loss of CHF 134 million for the quarter.
The net profit figure for 2012 reflects the fundamental strength of the biotech
sector and the successful investment strategy pursued by BB Biotech with clearly
defined areas of focus. BB Biotech's share price rose 42.7% in CHF and 42.9% in
EUR during the past year.
Portfolio holdings as of December 31, 2012 will be reported on January
24, 2013. The annual report for 2012 will be published on February 21, 2013.
For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Thomas Egger, Tel. +41 44 267 67 09, email@example.com
BB Biotech invests in companies in the fast growing market of biotechnology and
is one of the world's largest investors in this sector with approx. CHF 1.2
billion in assets under management. BB Biotech is listed in Switzerland, Germany
and Italy. Its investments are focused on listed companies that are developing
and commercializing novel medical treatments and cures. BB Biotech's investment
selection process is guided by the fundamental research and analysis of
physicians and molecular biologists. Its Board of Directors has many years of
experience in industry and science.
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BB BIOTECH AG via Thomson Reuters ONE